Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus–HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation

The Journal of Infectious Diseases(2020)10.1093/infdis/jiaa254Source: DataRank Database

Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus–HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation is a research paper published in The Journal of Infectious Diseases (2020). On theSindex it has a DataRank of 0.497. It has been cited 12 times, with 7 citing works in its 1-hop citation network.

N/A

0.497DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access12 citations · 7 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02194998

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 0.57)OA: greenTopics (100)IDs (PubMed, OpenAlex)SDGs (4)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 77%Citation Network 23%

Base Score Contribution

0.385

From this paper's citation signal

Citation Network Contribution

0.112

From 6 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 7 citers.

Trends and Demographics of Liver Fibrosis and Cirrhosis‐Related Mortality Among Adults Living in the United States From 1999 to 2020: A CDC Wonder Analysis
JGH Open20252 citations29 referencesContributes 0.038
HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
Frontiers in Immunology202125 citations102 referencesContributes 0.032
The clinical utility of CD163 in viral diseases
Clinica Chimica Acta202322 citations118 referencesContributes 0.027
Prodrug Therapies for Infectious and Neurodegenerative Diseases
Pharmaceutics202210 citations167 referencesContributes 0.014
Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy
Frontiers in Immunology20241 citations63 referencesContributes 0.011

Authors (11)

Mark Sulkowski ORCID,Laura Smeaton ORCID,Sofi Damjanovska ORCID,Carey L. Shive ORCID,Corinne Kowal

Live enrichment

PubMed:32406487 OpenAlex:https://openalex.org/W3025822722

AIDS Clinical Trials Group

Grant: UM1 AI106701

AIDS Clinical Trials Group

Grant: UM1 AI068634

Statistical and Data Management Center

Grant: IK2CX001471

Statistical and Data Management Center

Grant: BX001894

Statistical and Data Management Center

Grant: CX001791

Statistical and Data Management Center

Grant: K24DA034621

National Institutes of Health

Grant: 5K24DA034621-10

Midcareer Investigator Award in Patient-Oriented Research (Parent K24)

National Institutes of Health

Grant: 1IK2CX001471-01A1

Role of IL-6 and IL-1b in immune dysfunction during aging, HIV, and HCV infection

National Institutes of Health

Grant: 5UM1AI068634-09

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)

NIAID NIH HHS

Grant: R01 AI116868

BLRD VA

Grant: I01 BX001894

NIAID NIH HHS

Grant: UM1 AI069424

NIAID NIH HHS

Grant: U01 AI068634

NIAID NIH HHS

Grant: UM1 AI068636

FWCI

0.57

Citation Percentile

0.6%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: public-domain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7749191

publisherhttp://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiaa254/33388269/jiaa254.pdf

publisherhttp://academic.oup.com/jid/article-pdf/222/8/1334/35001076/jiaa254.pdf

journalhttps://doi.org/10.1093/infdis/jiaa254

Fields of Study

Hepatitis C virus researchHIV-related health complications and treatmentsHIV Research and Treatment0301 basic medicine03 medical and health sciences0303 health sciences2-NaphthylamineAdultAnilidesAnti-HIV AgentsAntiviral AgentsBiomarkersCarbamatesCoinfectionCyclopropanesDrug Therapy, CombinationFemaleGenotypeHIV InfectionsHIV-1HepacivirusHepatitis C, ChronicHumansImmunologic FactorsLactams, MacrocyclicLiver CirrhosisMaleMiddle AgedProlineRibavirinRitonavirSulfonamidesSustained Virologic ResponseUracilValine

MeSH Terms

Sustained Virologic ResponseAdultAnilidesAntiviral AgentsCarbamatesCyclopropanesDrug Therapy, CombinationFemaleGenotypeHumansImmunologic FactorsLiver CirrhosisMaleMiddle AgedProlineRibavirinSulfonamidesUracilValine2-NaphthylamineBiomarkersHIV-1HIV InfectionsHepacivirusAnti-HIV AgentsRitonavirHepatitis C, ChronicLactams, MacrocyclicCoinfection

Keywords

OmbitasvirParitaprevirDasabuvirCoinfectionRitonavirHepatitis C virusMedicineHepatitis CVirologyImmunologyViral loadRibavirinVirusAdultCyclopropanesLiver CirrhosisGenotypeAnti-HIV AgentsLactams, MacrocyclicHIV InfectionsHepacivirusAntiviral Agents2-NaphthylamineHumansImmunologic FactorsAnilidesHepatitis C, ChronicHIV-1Drug Therapy, CombinationFemaleCarbamatesBiomarkersDAA therapyhumanimmunityinflammation

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good healthSDG 12: 12. Responsible consumptionSDG 0: Good health and well-being